СПИСОК ЛИТЕРАТУРЫ

1.Champion G.D, Feng P.H„ Azuma T. et al. NSAID-induced gastrointestinal damage // Drugs, 1997, 53: 6-19.

2.Laurence D.R., Bennett P.N. Clinical Pharmacology. 7th ed. Churcill Livingstone. 1992.

3.Insel P.A. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Goodman & Gilman's. The pharmacological basis of therapeutics. 9th ed. McGraw-Hill, 1996, 617-657.

4.Носонов Е.Л. Нестероидные противовоспалительные препараты в ревматологии // лечащий врач. 2006.№2.

5.Нестероидные противовоспалительные средства (Редакц. статья) // Клин. фармакол. и фармакотер., 1994, 3, 6-7.

6.Ушкалова Е.А., Зыряерв С.К., Переверзев А.П. Клиническая фармакология нестероидных противовоспалительных средств. Москва, 2018. http:www.medkniga.ru.

7.Кетова Г.Г., Астапенкова Ю.В. НПВС-ассоциированная патология верхних отделов ЖКТ: факторы риска, тактика ведения пациентов. Взгляд клинического фармаколога // РМЖ. 2014. №18. С.1326-1329.

8.Meek I.L., van de Laar M.A., Vonkeman H.E. Non-steroidal anti-inflammatory drugs: an overview of cardiovascular risk //Pharmaceuticals. 2010. V.3. P.2146-2162.

9.Meek I.L., Vonkeman H.E., Kasemier J.et al. Interference of NSAIDs with th thrombocyte inhibitory effect of aspirini: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study // Eur. J. Clin. Pharmacol. 2013. V. 69(3). P. 365-371.

10.Masferrer J. L., Zweifel B.S., Seibert T., Needleman P. // J. Clin. Invest.— 1990.—V.86.—Р.1375— 1379. , 27.

11.Meade F.A., Smith W.L.,De Witt D.I. //J. Biol. Chem. — 1993. — V. 268. —Р. 6610—6614.

12.Warner T.D., Giuliano F., Vojnovic I. et al. //Proc. Natl. Acad. Sci. USA.— 1999.—N 96.—P.7563— 7568.

13.Wang L.H., Hajibeigi A., Xu X.M. et al. // Biochem. Byophys. Res. Commun.— 1993.—V.190.— Р.406—411

14.Loeb D.S., Ahlquist D.A., Talley N.J. Management of gastroduo-denopathy associated with use of nonsteroidal anti-inflammatory drugs // Mayo Clin. Proc., 1992, 67: 354-364.

1.Espinosa L., Lipani J., Poland M., Wallin B. Perforations, ulcers and bleeds in a large, randomized, multicenter trial of namubetone compared with diclofenac, ibuprofen, naproxen and piroxicam // Rev. Esp. Reumatol., 1993, 20 (suppl. I): 324.

2.Brooks P.M., Day R.O. Nonsteroidal antiinfla mmatory drugs – differences and similarities // N. Engl. J. Med., 1991, 324: 1716-1725.

3.Lieber C.S. Medical disorders of alcoholism // N. Engl. J. Med., 1995, 333: 1058-1065.

4.Guslandi M. Gastric toxicity of antiplatelet therapy with low-dose aspirin // Drugs, 1997, 53: 1-5.

5.Applied Therapeutics: The clinical use of drugs. 6th ed. Young L.Y., Koda-Kimble M.A. (Eds). Vancouver. 1995.

6.Drugs of choice from the Medical Letter. New York. Revised ed. 1995.

7.Marcus A.L. Aspirin as prophilaxis against colorectal cancer // N. Engl.J. Med.,1995, 333: 656-658

8.Noble S, Balfour J. Meloxicam // Drugs, 1996, 51: 424-430.

9.Konstan M.W., Byard PJ., Hoppel C.L., Davis P.B. Effect of high dose ibuprofen in patients with cystic fibrosis // N. Engl. J. Med., 1995, 332: 848-854.

10.Perneger T.V., Whelton P.К., Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs // N. Engl. J. Med, 1994, 331: 1675-1712.

70

11.Merck Manual of Diagnosis and Therapy. 16th ed. Berkow R. (Ed.). Merck & Co Inc., 1992.

12.Gillis J.C., Brogden R.N. Ketorolak. A reappraisal of its pharmacodinamic and pharmacokinetic properties and therapeutic use in pain management // Drugs, 1997, 53: 139188.

13.Rigas B., Tsioulias G.J. The evolving role of nonsteroidal anti-inflammatory drugs in color cancer prevention: a cause for optimism //J. Pharmacol. Exp. Ther. 2015. V.353(1).P.2-8.

14.Huntv R.H., Yuan Y., Acid-NSAID/aspirin interaction in peptic ulcer disease // Dis. 2011. V. 29(5). P.465-468.

15.Chen L.C., Ashcroft D.M. Do selective COX-2 inhibitors increase the risk of cerebrovascular

events? A meta-analysis of randomized controlled trials // Pharmacoepidemiol. Drug Saf. 2007. V. 31(6). P.565-576.

16. European Medicine Agency Public Statement. European Medicine announces regulatory action on COX—2 inhibitors. Februaru 17, 2005. Available at http:// http://www.emea.eu.in/htms/hotpress/d62.75705htm. Accessed April 20,2005.

17.Backman S.B., Bondy R.M., Deschamps A. et al. Perioperative considerations for anesthesia // In: ACS Surgery: Principles Practice / Eds. W.W. Fink, G.J. et al. 6th ed. New York, NY: WebMD Professional Publishing, 2008.

18.Brooks J., Warburton R., Beales I.L. Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance // Ther. Adv. Chronic. Dis. 2013. V. 4(5). P. 206222.

19.Crofford L.J., Use of NSAIDs in treating patients with arthritis // Arthritis Res. Ther. 2013. V. 15. Suppl. S2.

20.Douketis J.D., Berger P.B., Dunn A.S. et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. // Chest. 2008. V. 133. Suppl. 6. 299S-339S.

21.Hinz B., Brune K. Paracetamol and cyclooxygenase inhibition: is there a cause for concern? // Ann. Rheum. Dis. 2012. V. 71. P. 20-25.

22.Hooper L., Brown T.J., Elliott et al. The effectiveness of fire strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review // BMJ. 2004. V. 329. P. 948-957.

23.Meriman E., Tran H. Antiplatelet drugs, anticoagulants and elective surgery // Aust. Analg. 2012. V. 114(2). P. 139-143.

24.Rostom A., Moayyedi P., Hunt R. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: Benefits versus risks // Aliment. Pharmacol. Ther. 2009. V. 29. P. 481.

25.Targownik L., Metge C., Leung S., Chateau D. The relative efficacies flammatory drugs // Gastroenterol. 2008. V. 134. P. 937-944.

26.Weir M.R. Renal effects of nonselective NSAIDs and coxibs // Cleve. Clin. J. Med. 2002. V. 69. Suppl. 1. S153-158.

71